Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Clene (NASDAQ:CLNN) in a research note published on Tuesday,Benzinga reports. D. Boral Capital currently has a $23.00 price target on the stock.

A number of other equities analysts have also recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Clene in a report on Thursday, November 14th. Canaccord Genuity Group reduced their price target on Clene from $86.00 to $83.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, Benchmark reduced their price target on Clene from $90.00 to $84.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $55.25.

Clene Price Performance

Shares of NASDAQ CLNN opened at $4.27 on Tuesday. The stock has a market capitalization of $35.55 million, a price-to-earnings ratio of -0.81 and a beta of 0.24. The business has a 50-day moving average of $4.81 and a 200-day moving average of $5.05. Clene has a fifty-two week low of $3.82 and a fifty-two week high of $10.40.

Institutional Investors Weigh In On Clene

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Clene by 52.9% during the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after acquiring an additional 22,539 shares during the period. Parsons Capital Management Inc. RI acquired a new stake in shares of Clene in the fourth quarter valued at approximately $194,000. Renaissance Technologies LLC acquired a new stake in shares of Clene in the fourth quarter valued at approximately $96,000. SBI Securities Co. Ltd. acquired a new stake in shares of Clene in the fourth quarter valued at approximately $69,000. Finally, Fullcircle Wealth LLC acquired a new stake in shares of Clene in the fourth quarter valued at approximately $69,000. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.